Banerjee Subho, Patel Himanshu V, Engineer Divyesh P, Gupta Vaibhav, Patel Harshit, Gupta Aakash, Shah Pankaj R, Kute Vivek B
Department of Nephrology, Institute of Kidney Diseases and Research Center and Institute of Transplant Sciences (IKDRC-ITS), Ahmedabad, Gujarat, India.
Indian J Nephrol. 2022 May-Jun;32(3):216-222. doi: 10.4103/ijn.IJN_575_20. Epub 2021 Dec 30.
Chronic kidney disease patients on hemodialysis (CKD-5D) are among the worst hit by the coronavirus disease 2019 (COVID-19) pandemic. Need to travel for dialysis, comorbidities, and immunosuppressive state put them at risk of severe disease and poor outcomes. We report our experience of COVID-19 in a cohort of CKD-5D from a public sector tertiary-care center from western India.
We retrospectively analyzed the records of 58 CKD-5D patients with confirmed COVID-19 admitted to our COVID-19 hospital. Suspected COVID-19, acute kidney injury (AKI), or AKI on CKD were excluded. We studied the clinical, demographic, radiological, and laboratory profiles; treatment; and outcomes of the patients. We assessed the potential clinical and laboratory parameters to predict mortality.
The mean age of the patients was 48.7 ± 16.9 years, with 55% males. Comorbidities included hypertension (65%), diabetes (19%), and cardiovascular disease (15.5%). The presenting features included fever (69%), respiratory distress (50%), upper respiratory symptoms (36%), and diarrhea (13%). Five (8.6%) were asymptomatic. Bilateral infiltrates on chest imaging were the commonest radiological pattern. The patients were managed with oxygenation, hydroxychloroquine, steroids, anticoagulation, remdesivir, and favipiravir. Twenty-two (37.9%) patients died, predominantly due to respiratory failure. Disease severity and C-reactive protein (CRP) above 175 mg/L at admission were the only parameters predictive of mortality.
CKD-5D patients with COVID-19 were less likely to present with the classical syndrome of fever and respiratory distress compared with reports from the general population and had higher mortality. Only disease severity and high CRP (>175 mg/L) were predictive of mortality in our cohort.
接受血液透析的慢性肾脏病患者(CKD-5D)是2019冠状病毒病(COVID-19)大流行中受影响最严重的人群之一。因需要前往外地进行透析、合并症以及免疫抑制状态,使他们面临罹患重症和不良预后的风险。我们报告了来自印度西部一家公立三级医疗中心的一组CKD-5D患者感染COVID-19的情况。
我们回顾性分析了58例确诊感染COVID-19并入住我院COVID-19病房的CKD-5D患者的记录。排除疑似COVID-19、急性肾损伤(AKI)或CKD基础上的急性肾损伤患者。我们研究了患者的临床、人口统计学、影像学和实验室检查结果;治疗情况;以及患者的预后。我们评估了预测死亡率的潜在临床和实验室参数。
患者的平均年龄为48.7±16.9岁,其中男性占55%。合并症包括高血压(65%)、糖尿病(19%)和心血管疾病(15.5%)。临床表现包括发热(69%)、呼吸窘迫(50%)、上呼吸道症状(36%)和腹泻(13%)。5例(8.6%)患者无症状。胸部影像学双侧浸润是最常见的影像学表现。患者接受了氧疗、羟氯喹、类固醇、抗凝、瑞德西韦和法匹拉韦治疗。22例(37.9%)患者死亡,主要原因是呼吸衰竭。疾病严重程度和入院时C反应蛋白(CRP)高于175mg/L是仅有的预测死亡率的参数。
与普通人群的报告相比,感染COVID-19的CKD-5D患者出现发热和呼吸窘迫典型综合征的可能性较小,且死亡率较高。在我们的队列中,只有疾病严重程度和高CRP(>175mg/L)可预测死亡率。